Literature DB >> 6441771

A unique human B lymphocyte antigen defined by a monoclonal antibody.

T C Meeker, R A Miller, M P Link, J Bindl, R Warnke, R Levy.   

Abstract

We produced a hybridoma designated 4G7 from a mouse immunized with chronic lymphocytic leukemia cells. The 4G7 hybridoma secretes an IgG1 antibody that is specific for normal and malignant B lymphocytes. Using dual color immunofluorescence staining, this antibody reacted with all immunoglobulin-positive cells but no T cells in normal peripheral blood. There was no detectable 4G7 antigen on monocytes, platelets, red cells, granulocytes, or phytohemagglutinin-activated T cells. When PBL were depleted of 4G7 positive cells and stimulated with pokeweed mitogen, secreted immunoglobulin levels fell to less than 10% of control values on Day 5 and less than 1% of control on Day 7. This antibody was reactive with 155 of 176 B lineage neoplasms on which it was screened. Thirty-five cases of myeloid or T-lymphoid malignancy were negative. Our studies show that the 4G7 antigen modulates in the presence of excess antibody. Free 4G7 antigen was not found circulating in human serum. The cell surface antigen identified by 4G7 was sensitive to pronase proteolysis but resistant to trypsin and chymotrypsin digestion. A comparison of 4G7 with other known B-cell antibodies indicates that the 4G7 antigen has not been previously identified. This antibody is of use for the identification of normal B lymphocytes, the study of B-cell differentiation, and the characterization of lymphoid malignancies.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6441771     DOI: 10.1089/hyb.1984.3.305

Source DB:  PubMed          Journal:  Hybridoma        ISSN: 0272-457X


  22 in total

1.  Discordance between surface and cytoplasmic expression of the Leu-4 (T3) antigen in thymocytes and in blast cells from childhood T lymphoblastic malignancies.

Authors:  M P Link; S J Stewart; R A Warnke; R Levy
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

2.  Engagement of CD81 induces ezrin tyrosine phosphorylation and its cellular redistribution with filamentous actin.

Authors:  Greg P Coffey; Ranjani Rajapaksa; Raymond Liu; Orr Sharpe; Chiung-Chi Kuo; Sharon Wald Krauss; Yael Sagi; R Eric Davis; Louis M Staudt; Jeff P Sharman; William H Robinson; Shoshana Levy
Journal:  J Cell Sci       Date:  2009-08-04       Impact factor: 5.285

3.  Immunomodulation by methimazole therapy in Graves' disease: rapid changes in activation stage of circulating regulatory T cell subsets, B cells and NK cells.

Authors:  F A Karlsson; T H Tötterman
Journal:  Clin Exp Immunol       Date:  1988-11       Impact factor: 4.330

4.  Lymphoid cell subsets in normal human small intestine.

Authors:  M Chiba; H Ohta; A Nagasaki; H Arakawa; O Masamune
Journal:  Gastroenterol Jpn       Date:  1986-08

5.  Extraction of immune and inflammatory cells from human lung parenchyma: evaluation of an enzymatic digestion procedure.

Authors:  P G Holt; B W Robinson; M Reid; U R Kees; A Warton; V H Dawson; A Rose; M Schon-Hegrad; J M Papadimitriou
Journal:  Clin Exp Immunol       Date:  1986-10       Impact factor: 4.330

6.  Marked increase of CD5 + B cells in hyperthyroid Graves' disease.

Authors:  Y Iwatani; N Amino; T Kaneda; K Ichihara; H Tamaki; J Tachi; F Matsuzuka; S Fukata; K Kuma; K Miyai
Journal:  Clin Exp Immunol       Date:  1989-11       Impact factor: 4.330

7.  The influence of age, race, and gender on peripheral blood mononuclear-cell subsets in healthy nonsmokers.

Authors:  D J Tollerud; J W Clark; L M Brown; C Y Neuland; L K Pankiw-Trost; W A Blattner; R N Hoover
Journal:  J Clin Immunol       Date:  1989-05       Impact factor: 8.317

8.  Primary malignant lymphoma of the brain: an immunohistochemical study of eight cases using a panel of monoclonal and heterologous antibodies.

Authors:  T Kumanishi; K Washiyama; T Saito; A Nishiyama; S Abe; T Tanaka
Journal:  Acta Neuropathol       Date:  1986       Impact factor: 17.088

9.  A single-chain triplebody with specificity for CD19 and CD33 mediates effective lysis of mixed lineage leukemia cells by dual targeting.

Authors:  Ingo Schubert; Christian Kellner; Christoph Stein; Markus Kügler; Michael Schwenkert; Domenica Saul; Kristin Mentz; Heiko Singer; Bernhard Stockmeyer; Wolfgang Hillen; Andreas Mackensen; Georg H Fey
Journal:  MAbs       Date:  2011-01-01       Impact factor: 5.857

10.  The antitumor activity and immunosuppressive effects of 5-fluorouracil suppositories in rectal cancer patients.

Authors:  W Adachi; A Sugenoya; N Horigome; C Takahashi; F Iida; J Nakayama
Journal:  Surg Today       Date:  1992       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.